News & Events RSS Feed

28 November 2013

Physiomics launches new DrugCARD® database for oncology researchers and clinicians

Physiomics is pleased to announce that it has now launched its Drug Combinations and Regimens database. DrugCARD® collates curated publicly available pre-clinical and clinical drug regimen data into one easily searchable tool. It also contains further clinical data and analysis which is only available through the collaboration with Pharmacometrics. Read more.

28 November 2013

Physiomics is recruiting: Biosimulation Scientist

We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development. Find more details at our careers page.

11 November 2013

Physiomics to collaborate with the University of Oxford and the Oxford University Hospitals NHS trust on its Virtual Tumour Clinical research program

Physiomics is pleased to announce that it has signed a collaboration agreement with the University of Oxford and the Oxford University Hospitals NHS trust to support the development of Physiomics’ flagship Virtual Tumour Clinical technology. Virtual Tumour Clinical is used to predict optimal clinical regimens for cancer trials. Physiomics has been seeking academic and industrial […]

4 November 2013

Physiomics to update on the Virtual Tumour Clinical platform at the 2013 NCRI Cancer Conference

Physiomics is pleased to announce that it is participating in the 2013 NCRI Cancer Conference, taking place at the BT Convention Centre, Liverpool, on 3-6 November 2013. Dr Eric Fernandez, Project Leader, will present details of the on-going development of the Virtual Tumour Clinical platform. The abstract ("Dosing and schedule optimization with Virtual Tumour Clinical […]

7 October 2013

Physiomics gains new speciality pharma customer for drug discovery research

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with a new speciality pharma customer, to investigate how one of its new candidate drugs shrinks tumours. Read more.

1 October 2013

Physiomics gains first large pharma customer for modelling cardiac toxicity risk

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services. Read more

16 September 2013

Physiomics to present on the cardiac toxicity platform at the 2013 Safety Pharmacology Society’s Annual Meeting (“SPS”)

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's  annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform […]

Page 3 of 1612345...10...Last